$1.21
(9.32%)
Create an alert
Stocks and Shares ISAKorro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Company Information
About this company
Key people
Nessan Bermingham
Independent Chairman of the Board
Ram Aiyar
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
Todd Chappell
Chief Operating Officer
Jeffrey Cerio
Senior Vice President, General Counsel, Corporate Secretary
Loic Vincent
Chief Scientific Officer
Ali Behbahani
Independent Director
Jean-Francois Formela
Independent Director
Katharine Knobil
Independent Director
Rachel Meyers
Independent Director
Click to see more
Key facts
- Shares in issue14.42m
- EPICKRRO
- ISINUS5009461089
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$193.41m
- Employees49
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.